Ms. Abbey Abdiye reports

BIOMARK ANNOUNCES PRIVATE PLACEMENT

Biomark Diagnostics Inc. has approved a non-brokered private placement. The placement offering will be for up to 1.5 million units at a price of 50 cents per unit to raise gross proceeds of up to $750,000.

Each unit will consist of one common share of Biomark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of Biomark at 80 cents per share for a period of one year from the closing date of the private placement. Finders' fees may be payable.

The warrants are subject to an accelerated expiry provision, where, if at any time after the closing date of the offering of the units, the closing price of the common share is $1 or higher for a period of 10 consecutive trading days, the company may provide notice by way of press release to the holder of the warrants of the early expiry of the warrants. Thereafter, the warrants shall expire on the date that is 30 days from the date that notice is given.

The proceeds of the private placement will be used for the continuation of the company's phase 3 clinical trials, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months and one day from the closing date of the private placement.

Certain insiders, directors and officers may subscribe for a portion of this placement.

We seek Safe Harbor.